Company will produce Trop-2 targeting antibody.

Laureate Pharma entered into a cGMP manufacturing agreement with Arius Research for its Trop-2 signal transduction antibody program.

Laureate will produce Arius’ IgG1 humanized antibody under the agreement. The product targets a novel marker that has been linked to aggressive cancers including pancreatic, colon, breast, and prostate cancer, according to Arius.

Previous articleInvestigators Reveal HTLV-1’s Mechanism for Inducing Leukemia/Lymphoma
Next articleScientists Identify Protein’s Role in Heart Attack Response